47,073 Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) Acquired by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. acquired a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 47,073 shares of the medical research company's stock, valued at approximately $15,464,000. Balyasny Asset Management L.P. owned 0.17% of Bio-Rad Laboratories as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in BIO. Venturi Wealth Management LLC grew its stake in shares of Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after buying an additional 87 shares during the last quarter. GeoWealth Management LLC grew its stake in shares of Bio-Rad Laboratories by 342.9% in the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock worth $31,000 after acquiring an additional 72 shares during the last quarter. Picton Mahoney Asset Management increased its holdings in shares of Bio-Rad Laboratories by 55.6% during the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock valued at $32,000 after acquiring an additional 35 shares in the last quarter. Asset Planning Inc bought a new position in Bio-Rad Laboratories in the 4th quarter worth about $33,000. Finally, UMB Bank n.a. grew its position in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after purchasing an additional 32 shares during the last quarter. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Performance

BIO traded down $2.20 during mid-day trading on Friday, reaching $238.82. 244,720 shares of the company traded hands, compared to its average volume of 319,090. The company's fifty day moving average price is $244.34 and its 200-day moving average price is $301.12. The stock has a market capitalization of $6.69 billion, a P/E ratio of -3.67 and a beta of 1.00. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 52-week low of $215.38 and a 52-week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, beating analysts' consensus estimates of $1.73 by $0.81. The company had revenue of $585.40 million during the quarter, compared to analysts' expectations of $573.01 million. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Bio-Rad Laboratories's revenue for the quarter was down 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.30 earnings per share. On average, sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Citigroup decreased their target price on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a report on Friday, May 2nd. StockNews.com cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Wells Fargo & Company reduced their target price on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. UBS Group lowered their price target on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Finally, Royal Bank of Canada dropped their price objective on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Bio-Rad Laboratories has a consensus rating of "Moderate Buy" and an average price target of $327.40.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.